PubRank

H Gabra

Author PubWeight™ 26.73‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci U S A 2001 2.79
2 A prognostic model for ovarian cancer. Br J Cancer 2001 2.77
3 c-myc oncogene expression in colorectal cancer. Cancer 1987 1.60
4 A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D. Cancer Res 2000 1.39
5 A novel tumour marker related to the c-myc oncogene product. Mol Cell Probes 1987 1.11
6 Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer. Br J Cancer 2009 1.07
7 Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogen. Clin Cancer Res 1998 0.99
8 High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour-suppressor loci. Br J Cancer 1996 0.96
9 BARX2 induces cadherin 6 expression and is a functional suppressor of ovarian cancer progression. Cancer Res 2001 0.94
10 Continuous 5-fluorouracil in the treatment of breast cancer. Br J Cancer 1994 0.92
11 Malignant mixed mesodermal tumours: biology and clinical aspects. Eur J Cancer 2002 0.90
12 Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells. Oncogene 2012 0.89
13 Expression of eEF1A2 is associated with clear cell histology in ovarian carcinomas: overexpression of the gene is not dependent on modifications at the EEF1A2 locus. Br J Cancer 2007 0.88
14 A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. Br J Cancer 2008 0.87
15 Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours. Cytokine 2013 0.86
16 Identification and characterization of a homozygous deletion found in ovarian ascites by representational difference analysis. Genome Res 1999 0.84
17 A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma. Ann Oncol 2009 0.83
18 A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. Ann Oncol 2012 0.83
19 Identification of a region of frequent loss of heterozygosity at 11q24 in colorectal cancer. Cancer Res 1999 0.82
20 Intra-uterine death resulting from placental metastases in adenocarcinoma of unknown primary. Clin Oncol (R Coll Radiol) 2002 0.82
21 High-dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancer--phase I/II study. Edinburgh Breast Group. Br J Cancer 1996 0.77
22 Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study. Ann Oncol 2013 0.76
23 Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer. Br J Cancer 2012 0.76
24 Sexual activity and functioning in ovarian cancer survivors: an internet-based evaluation. Climacteric 2014 0.75
25 A method for voltage measurements of cancerous vs non-cancerous omentum. Conf Proc IEEE Eng Med Biol Soc 2015 0.75
26 Immunological and gene therapy for ovarian cancer a technical overview. Methods Mol Med 2001 0.75
27 A protective role for common p21WAF1/Cip1 polymorphisms in human ovarian cancer. Int J Oncol 1999 0.75